Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
The DOI matches its Crossref record; 47 of the 47 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Patients with elevated triglyceride levels are at increased risk for ischemic events. Icosapent ethyl, a highly purified eicosapentaenoic acid ethyl ester, lowers triglyceride levels, but data are needed to determine its effects on ischemic events. METHODS: We performed a multicenter, randomized, double-blind, placebo-controlled trial involving patients with established cardiovascular disease or with diabetes and other risk factors, who had been receiving statin therapy and who had a fasting triglyceride level of 135 to 499 mg per deciliter (1.52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per deciliter (1.06 to 2.59 mmol per liter). The patients were randomly assigned to receive 2 g of icosapent ethyl twice daily (total daily dose, 4 g) or placebo. The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization, or unstable angina. The key secondary end point was a composite of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke. RESULTS: A total of 8179 patients were enrolled (70.7% for secondary prevention of cardiovascular events) and were followed for a median of 4.9 years. A primary end-point event occurred in 17.2% of the patients in the icosapent ethyl group, as compared with 22.0% of the patients in the placebo group (hazard ratio, 0.75; 95% confidence interval [CI], 0.68 to 0.83; P<0.001); the corresponding rates of the key secondary end point were 11.2% and 14.8% (hazard ratio, 0.74; 95% CI, 0.65 to 0.83; P<0.001). The rates of additional ischemic end points, as assessed according to a prespecified hierarchical schema, were significantly lower in the icosapent ethyl group than in the placebo group, including the rate of cardiovascular death (4.3% vs. 5.2%; hazard ratio, 0.80; 95% CI, 0.66 to 0.98; P=0.03). A larger percentage of patients in the icosapent ethyl group than in the placebo group were hospitalized for atrial fibrillation or flutter (3.1% vs. 2.1%, P=0.004). Serious bleeding events occurred in 2.7% of the patients in the icosapent ethyl group and in 2.1% in the placebo group (P=0.06). CONCLUSIONS: Among patients with elevated triglyceride levels despite the use of statins, the risk of ischemic events, including cardiovascular death, was significantly lower among those who received 2 g of icosapent ethyl twice daily than among those who received placebo. (Funded by Amarin Pharma; REDUCE-IT ClinicalTrials.gov number, NCT01492361 .).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Recent trials have studied higher dosages of omega-3 fatty acids, reporting a cardiovascular benefit in 2 trials of purified EPA. 10,11”
From Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk (2020) · cites this paper as [11]
In the citing paper
“O3CA lowered non-HDL-C by 6% and apo B by 2%, 41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“With regard to O3CA, the 2-g/d dose examined in the ESPRIT trial (Epanova Combined with a Statin in Patients with Hypertriglyceridemia to Reduce Non-HDL Cholesterol; ≈1.5 g/d EPA+DHA) reduced triglycerides by 9% versus 15% with 4 g/d.41”
From Omega-3 Fatty Acids for the Management of Hypertriglyceridemia: A Science Advisory From the American Heart Association (2019) · cites this paper as [41]
In the citing paper
“High‐dose eicosapentaenoic ethyl ester combined with baseline statins can lead to a remarkable decline in first and recurrent events in high‐risk patients with hypertriglyceridemia. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
In the citing paper
“Conversely, patients with hypertriglyceridemia treated with a medium‐to‐high dose of icosapent ethyl were less likely to develop ischemic events, including CVD death. 18 , 19”
From Association Between Omega-3 Fatty Acid Intake and Dyslipidemia: A Continuous Dose-Response Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [19]
126 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Self-citationIntensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634
Self-citationYokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Confidence intervals for the number needed to treat.
Altman, D. G. (1998) · BMJ · doi:10.1136/bmj.317.7168.1309 · Cited by 938
n–3 Fatty Acids and Cardiovascular Outcomes in Patients with Dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203859 · Cited by 929
Martin, S. S., Blaha, M. J., Elshazly, M. B., Toth, P. P., Kwiterovich, P. O., Blumenthal, R. S., & Jones, S. R. (2013) · JAMA · doi:10.1001/jama.2013.280532 · Cited by 883
Bhatt, D. L., Eagle, K. A., Ohman, E. M., Hirsch, A. T., Goto, S., Mahoney, E. M., Wilson, P. W. F., Alberts, M. J., D’Agostino, R., Liau, C.-S., et al. (2010) · JAMA · doi:10.1001/jama.2010.1322 · Cited by 753
Self-citationEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Cited by
Items 1,001–1,052 of 1,052
Djoussé, L., Cook, N. R., Kim, E., Walter, J. N., Al-Ramady, O. T., Luttmann‐Gibson, H., Albert, C. M., Mora, S., Buring, J. E., Gaziano, J. M., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2021.12.006 · Cited by 22
Gaba, P., Bhatt, D. L., Mason, R. P., Miller, M. J., Verma, S., Steg, P. G., & Boden, W. E. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.05.067 · Cited by 23
Self-citationGurevitz, C., & Rosenson, R. S. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae388 · Cited by 19
Lipidomics of triglyceride‐rich lipoproteins derived from hyperlipidemic patients on inflammation
Moreno‐Vedia, J., Llop, D., Rodríguez‐Calvo, R., Plana, N., Amigó, N., Rosales, R., Esteban, Y., Masana, L., Ibarretxe, D., & Girona, J. (2024) · European Journal of Clinical Investigation · doi:10.1111/eci.14132 · Cited by 19
Eicosapentaenoic acid vs. docosahexaenoic acid for the prevention of cardiovascular disease
Sweeney, T. E., Gaine, S. P., & Michos, E. D. (2023) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000796 · Cited by 18
Le, V. T., Knight, S., Watrous, J. D., Najhawan, M., Dao, K., McCubrey, R. O., Bair, T. L., Horne, B. D., May, H. T., Muhlestein, J. B., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1229130 · Cited by 18
Role of Omega-3 Fatty Acids in Improving Metabolic Dysfunctions in Polycystic Ovary Syndrome
Albardan, L., Platat, C., & Kalupahana, N. S. (2024) · Nutrients · doi:10.3390/nu16172961 · Cited by 18
“…ester (icosapent ethyl—4 g/day) reduced major cardiovascular events in patients with existing cardiovascular disease or diabetes and elevated plasma triglycerides [81], confirming that the triglyceride-lowering effects of these fatty acids also extend into cardio-protection in the longer term.”
BackgroundControversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis
Quispe, R., Alfaddagh, A., Kazzi, B., Zghyer, F., Marvel, F. A., Blumenthal, R. S., Sharma, G., & Martin, S. S. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01031-9 · Cited by 17
Mahmoud, A., Abdelsayed, K., Mohamed, A. A., Najah, Q., Abdulkader, A., Ali, K., Tabassum, S., Abouzid, M. R., Abdelazeem, B., & Mills, J. D. (2025) · Lipids in Health and Disease · doi:10.1186/s12944-024-02389-2 · Cited by 17
“However, cardiovascular and pancreatic outcome trials are essential to position such a regimen within the existing treatment paradigm for HTG [8, 9, 45, 46].”
The lipid paradox in neuroprogressive disorders: Causes and consequences
Morris, G., Berk, M., Walder, K., O’Neil, A., Maes, M., & Puri, B. K. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.06.017 · Cited by 17
Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions
Tramontano, D., Bini, S., Maiorca, C., Di Costanzo, A., Carosi, M., Castellese, J., Arizaj, I., Commodari, D., Covino, S., Sansone, G., et al. (2025) · Drugs · doi:10.1007/s40265-025-02158-0 · Cited by 17
The reduction in cardiovascular risk in REDUCE-IT is due to eicosapentaenoic acid in icosapent ethyl
Steg, P. G., & Bhatt, D. L. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab760 · Cited by 16
Self-citationMarkozannes, G., Ntzani, E. E., Tsapas, A., Mantzoros, C. S., Tsiara, S., Xanthos, T., Karpettas, N., Patrikios, I., & Rizos, E. C. (2022) · Clinical Nutrition · doi:10.1016/j.clnu.2022.02.022 · Cited by 16
Lessons from PROMINENT and prospects for pemafibrate
Fruchart, J.-C., Fruchart-Najib, J., Yamashita, S., Libby, P., Yokote, K., Kodama, T., Tomita, Y., Ridker, P. M., Hermans, M. P., & Zambon, A. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02305-z · Cited by 16
“…in LDL-C levels with high-dose icosapent ethyl ( supplement to publication ), but treat-ment was associated with 25% reduction in the primary composite endpoint (cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina requiring hospitalization) [40].”
BackgroundFish oil supplements may increase the risk for atrial fibrillation: what does this mean?
Samuel, M., & Nattel, S. (2021) · Circulation · doi:10.1161/circulationaha.121.057464 · Cited by 16
Women and diabetes: preventing heart disease in a new era of therapies
Galati, G., Sabouret, P., Germanova, O., & Bhatt, D. L. (2021) · European Cardiology Review · doi:10.15420/ecr.2021.22 · Cited by 15
Self-citationCardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Hvid, K., Balling, M., Afzal, S., & Nordestgaard, B. G. (2025) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaf203 · Cited by 15
Tomlinson, B., Chow, E., Chan, P., & Lam, C. W. K. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.2029402 · Cited by 15
“Triglyceride-rich lipoproteins are also recognized to contribute to ASCVD [5] and icosapent ethyl is endorsed for patients with persisting elevation of triglycerides after statin treatment, based on REDUCE-IT (The Reduction of Cardiovascular Events with EPA-Intervention Trial) [6].”
Spotlight on Icosapent Ethyl for Cardiovascular Risk Reduction: Evidence to Date
Jia, X., Koh, S., Al Rifai, M., Blumenthal, R. S., & Virani, S. S. (2020) · Vascular Health and Risk Management · doi:10.2147/vhrm.s210149 · Cited by 14
“98).(35) There was actually a lower rate of gastrointestinal adverse events, though this may be attributable to the use of mineral oil as the placebo.”
BackgroundResultTargeting RNA to lower triglycerides: long strides from short molecules
Qamar, A., Libby, P., & Bhatt, D. L. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz321 · Cited by 14
Self-citationRosenson, R. S., Rader, D. J., Ali, S., Banerjee, P., McGinniss, J., & Pordy, R. (2025) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-024-07567-z · Cited by 13
Marine Omega-3 Fatty Acids and Cardiovascular Disease Prevention: Seeking Clearer Water
Farukhi, Z. M., Mora, S., & Manson, J. E. (2021) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2020.12.013 · Cited by 12
Maki, K. C., Bays, H. E., Ballantyne, C. M., Underberg, J. A., Kastelein, J. J. P., Johnson, J. B., Ferguson, J. J., Bays, H., Blomer, A., Kelley, K., et al. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.121.024176 · Cited by 12
Self-citationOmega-3 and risk of atrial fibrillation: vagally-mediated double-edged sword
O'Keefe, E. L., O'Keefe, J. H., Abuissa, H., Metzinger, M., Murray, E., Franco, G., Lavie, C. J., & Harris, W. S. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.11.003 · Cited by 12
Bhatt, D. L., Steg, P. G., Miller, M., Juliano, R. A., & Ballantyne, C. M. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.08.007 · Cited by 11
Self-citationMiller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Pineda, A. L., Ketchum, S. B., Doyle, R. T., Tardif, J.-C., & Ballantyne, C. M. (2023) · European Heart Journal Open · doi:10.1093/ehjopen/oead114 · Cited by 11
Self-citationVirani, S. S., Nambi, V., & Ballantyne, C. M. (2021) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvab010 · Cited by 10
Self-citationOmega-3 Fatty Acids and Risk for Atrial Fibrillation
Ballantyne, C. M., & Jia, X. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.05.026 · Cited by 10
Self-citationBellosta, S., Rossi, C., Alieva, A. S., Catapano, A. L., Corsini, A., & Baragetti, A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-021-07293-w · Cited by 10
Nutrition, dietary recommendations, and supplements for patients with congenital heart disease
Lorente, M., Azpiroz, M. J., Guedes, P., Burgos, R., Lluch, A., & Dos, L. (2023) · International Journal of Cardiology Congenital Heart Disease · doi:10.1016/j.ijcchd.2023.100449 · Cited by 9
Yang, Z.-H., Gorusupudi, A., Lydic, T. A., Mondal, A. K., Sato, S., Yamazaki, I., Yamaguchi, H., Tang, J., Rojulpote, K. V., Lin, A. B., et al. (2023) · iScience · doi:10.1016/j.isci.2023.108411 · Cited by 9
Risk of Total Events With Icosapent Ethyl
Granger, C. B., Nelson, A. J., & Pagidipati, N. J. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.492 · Cited by 8
Reddin, C., Stankard, A., Chan, K. Y., Krewer, F., Judge, C., Canavan, M., Davis, D. H. J., & O’Donnell, M. (2025) · Age and Ageing · doi:10.1093/ageing/afaf219 · Cited by 8
Kim, J., Hoang, T., Kim, J.-M., Bu, S. Y., Choi, J.-H., Park, E., Lee, S.-M., Park, E., Min, J. Y., Lee, I. S., et al. (2020) · Nutrients · doi:10.3390/nu12103203 · Cited by 8
Lachaine, J., Charron, J.-N., Gregoire, J. C., Hegele, R. A., & Leiter, L. A. (2023) · ClinicoEconomics and Outcomes Research · doi:10.2147/ceor.s377935 · Cited by 7
Miller, M. (2024) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001136 · Cited by 7
Self-citationPrevalence of United States adults with triglycerides ≥ 135 mg/dL: NHANES 2007–2014
Fan, W., Philip, S., Toth, P. P., Granowitz, C., & Wong, N. D. (2019) · Cardiology Journal · doi:10.5603/cj.2019.0099 · Cited by 6
Self-citationAshraf, T., Devi, N., Aradhna, F., Devi, S., Nancy, F., Kumar, A., Ameer, F., Absar, F., Kumar, L., Kumar, S., et al. (2025) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000003505 · Cited by 6
“…cardiovascular outcomes with omega-3 fatty acids suggests that while they are effective in reducing TGs, their impact on cardiovascular risk is not uniform across different studies, which may be attributed to differences in study design, patient populations, and omega-3 formulations [ 44 , 45 ] .”
Fibrates : Do They Still Have a Role in Therapy in 2025?
Pirillo, A., Zambon, A., & Catapano, A. L. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-025-01379-8 · Cited by 4
“Icosa-pent ethyl, a highly purified omega-3 fatty acid, showed a significant 25% relative reduction in major cardiovascular events in the REDUCE-IT trial, establishing it as the first triglyceride-lowering agent with clear outcome efficacy [ 32].”
Alam, U., Mathai, S. V., Filtz, A., Kuno, T., Badimon, J. J., Sniderman, A. D., Virani, S. S., Toth, P. P., Shapiro, M. D., Lavie, C. J., et al. (2026) · Current Cardiology Reports · doi:10.1007/s11886-025-02337-1 · Cited by 4
Self-citationSheppard, J. P., Palatnic, L., Lakshmanan, S., Drago, T., Bhogal, J., Roy, S. K., Bhatt, D. L., Budoff, M. J., & Nelson, J. R. (2025) · JACC: Advances · doi:10.1016/j.jacadv.2025.102149 · Cited by 3
Self-citationAPOC3 inhibition: The strongest case yet for triglyceride targeting
Shapiro, M. D., & Slipczuk, L. (2025) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2025.09.006 · Cited by 2
Bernasconi, A. A., Maki, K. C., & Finkelstein, E. A. (2025) · Value in Health · doi:10.1016/j.jval.2025.07.005 · Cited by 2
Icosapent Ethyl Supplementation and Cardiovascular Prevention—Implications of Evolving Data
Wilkins, J. T., & Lloyd-Jones, D. M. (2022) · JAMA Cardiology · doi:10.1001/jamacardio.2022.3701 · Cited by 2
Elbahloul, M. A., Gamal, A., Maihoub, O., Elbaz Hassan, M. M., Attia, M. K., Salah, A. M., Elboraay, T., Awad, A. K., Akoum, A., Elazab, A., et al. (2026) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.70717 · Cited by 1
Abuknesha, N. R., O’Keefe, J. H., Qian, F., Tintle, N. L., Lin, Y., Sun, Y., Qian, H.-Z., Aisen, P. S., Albert, C. M., Aronson, W. J., et al. (2026) · Circulation: Arrhythmia and Electrophysiology · doi:10.1161/circep.125.014785 · Cited by 1
Sattar, Y., & Alraies, M. C. (2024) · Annals of Medicine & Surgery · doi:10.1097/ms9.0000000000002215 · Cited by 1
“We found that IPE is a highly puri fi ed prescribed ester form of EPA rather than EPA, and this terminology varies in different major clinical trials [4 – 6] .”
BackgroundTargeting triglycerides for cardiovascular risk reduction
Maiorca, C., Tramontano, D., Di Costanzo, A., & D’Erasmo, L. (2026) · Internal and Emergency Medicine · doi:10.1007/s11739-026-04383-1
Widjaja, J. S., Adji, A. S., Baraja, A., Dharmasaputra, A., Rosyadi, R. N., Komalasari, I., Mustofa, A., Multazam, C. E. C. Z., Alkaff, F. F., & Saputra, P. B. T. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179420
Icosapent ethyl reduces CVD risk in cardiovascular-kidney-metabolic syndrome: REDUCE-IT CKM
Miller, M., Bhatt, D. L., Brinton, E. A., Jacobson, T. A., Steg, P. G., Ketchum, S. B., Pineda, A. L., Tardif, J.-C., & Ballantyne, C. M. (2026) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101387
“…in a consensus statement by the European Athero-sclerosis Society [10] Previous studies have demonstrated a heightened risk of CVD events with pre-existing CVD [11], as well as an increased likelihood of major adverse CVD events associated with elevated TG [12], as evidenced in REDUCE-IT [8].”
InfluentialSelf-citationSkrabic, R., Kumric, M., Santic, R., Skrabic, I., Pavlovic, N., Rusic, D., & Bozic, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1875074
Metadata
- Authors
- Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., Tardif, J.-C., & Ballantyne, C. M.
- Affiliations
- Brigham and Women's Hospital (US)
- From Brigham and Women’s Hospital Heart and Vascular Center and Harvard Medical School, Boston (D.L.B.); FACT (French Alliance for Cardiovascular Trials), Département Hospitalo-Universitaire FIRE (Fibrose, Inflammation, and Remodeling), Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Université Paris-Diderot, INSERM Unité 1148, Paris (P.G.S.); National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the Department of Medicine, University of Maryland...
- University of Maryland, Baltimore (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-01-03
- Volume
- 380
- Issue
- 1
- Pages
- 11-22
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899669642
- Cited by
- 3,317
- References
- 47
- Citations by year
- 2026: 327 · 2025: 354 · 2024: 377 · 2023: 430 · 2022: 427 · 2021: 481 · 2020: 518 · 2019: 362
- FWCI
- 286.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Amarin
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- icosapent ethyl, eicosapentaenoic acid ethyl ester, hypertriglyceridemia, cardiovascular risk reduction, ischemic events, cardiovascular mortality, myocardial infarction, stroke, coronary revascularization, unstable angina, statin therapy, omega-3 fatty acids, secondary prevention, triglyceride-lowering therapy, LDL cholesterol, diabetes mellitus
- MeSH terms
- Aged, Cardiovascular Diseases, Double-Blind Method, Drug Administration Schedule, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Male, Middle Aged, Platelet Aggregation Inhibitors, Risk Factors, Triglycerides, Eicosapentaenoic Acid, Hypertriglyceridemia, Incidence, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Kaplan-Meier Estimate, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.